院外心脏骤停后肾上腺素与高级气道置入的顺序
该队列研究分析日本全国院外心脏骤停登记数据,纳入2014年1月1日至2019年12月31日期间接受肾上腺素和/或高级气道置入的成人患者259237例。采用倾向评分和逆概率治疗加权控制混杂后,先肾上腺素组较先气道组1个月生存率更高:可除颤心律OR 1.19(95%CI 1.09-1.30),不可除颤心律OR 1.28(95%CI 1.19-1.37)。次要终点良好功能状态和院前自主循环恢复也均升高。作者认为先给肾上腺素可能是改善预后的最佳顺序。
要点
- 可除颤心律患者先肾上腺素较先高级气道1个月生存率更高(OR 1.19,95%CI 1.09-1.30)。
- 不可除颤心律患者先肾上腺素较先高级气道1个月生存率更高(OR 1.28,95%CI 1.19-1.37)。
- 两种心律下先肾上腺素组的良好功能状态和院前自主循环恢复可能性均增加。
- 研究纳入成人院外心脏骤停患者259237例,中位年龄79(IQR 69-86)岁,男性占58.7%。
- 可除颤初始心律占8.3%(21592例),不可除颤初始心律占91.7%(237645例)。
适用人群与场景
- 日本全国、基于人群的院外心脏骤停登记中年龄≥18岁的成人患者。
- 纳入2014年1月1日至2019年12月31日期间由急救医疗服务人员给予肾上腺素和/或置入高级气道的患者。
- 按初始心律分为可除颤心律亚组(21592例,8.3%)和不可除颤心律亚组(237645例,91.7%)。
研究设计与关键结果
- 研究类型为队列研究,使用日本全国、基于人群的院外心脏骤停登记数据,共纳入259237例患者。
- 暴露为静脉肾上腺素给药与高级气道管理(声门上气道置入和气管插管)的顺序,比较先肾上腺素组与先高级气道组。
- 主要终点为1个月生存;采用倾向评分和逆概率治疗加权后,先肾上腺素组1个月生存率高于先高级气道组:可除颤心律OR 1.19(95%CI 1.09-1.30),不可除颤心律OR 1.28(95%CI 1.19-1.37)。
- 次要终点为1个月良好功能状态生存和院前自主循环恢复;先肾上腺素组在可除颤和不可除颤心律中上述终点可能性均增加。
- 加权后两组间所有协变量的标准化均数差均小于0.100;数据分析于2022年10月1日至2023年5月12日进行。
证据类型、等级与局限
- 证据类型:队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于院外心脏骤停患者,先给予肾上腺素再置入高级气道可能是改善预后的最佳治疗顺序。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: While epinephrine and advanced airway management (AAM) (supraglottic airway insertion and endotracheal intubation) are commonly used for out-of-hospital cardiac arrest (OHCA), the optimal sequence of these interventions remains unclear.
OBJECTIVE: To evaluate the association of the sequence of epinephrine administration and AAM with patient outcomes after OHCA.
DESIGN, SETTING, AND PARTICIPANTS: This cohort study analyzed the nationwide, population-based OHCA registry in Japan and included adults (aged ≥18 years) with OHCA for whom emergency medical services personnel administered epinephrine and/or placed an advanced airway between January 1, 2014, and December 31, 2019. The data analysis was performed between October 1, 2022, and May 12, 2023.
EXPOSURE: The sequence of intravenous epinephrine administration and AAM.
MAIN OUTCOMES AND MEASURES: The primary outcome was 1-month survival. Secondary outcomes were 1-month survival with favorable functional status and prehospital return of spontaneous circulation. To control imbalances in measured patient demographics, cardiac arrest characteristics, and bystander and prehospital interventions, propensity scores and inverse probability of treatment weighting (IPTW) were performed for shockable and nonshockable initial rhythm subcohorts.
RESULTS: Of 259 237 eligible patients (median [IQR] age, 79 [69-86] years), 152 289 (58.7%) were male. A total of 21 592 patients (8.3%) had an initial shockable rhythm, and 237 645 (91.7%) had an initial nonshockable rhythm. Using IPTW, all covariates between the epinephrine-first and AAM-first groups were well balanced, with all standardized mean differences less than 0.100. After IPTW, the epinephrine-first group had a higher likelihood of 1-month survival for both shockable (odds ratio [OR], 1.19; 95% CI, 1.09-1.30) and nonshockable (OR, 1.28; 95% CI, 1.19-1.37) rhythms compared with the AAM-first group. For the secondary outcomes, the epinephrine-first group experienced an increased likelihood of favorable functional status and prehospital return of spontaneous circulation for both shockable and nonshockable rhythms compared with the AAM-first group.
CONCLUSIONS AND RELEVANCE: These findings suggest that for patients with OHCA, administration of epinephrine before placement of an advanced airway may be the optimal treatment sequence for improved patient outcomes.
参考来源
- Okubo M, Komukai S, Izawa J, et al. Sequence of Epinephrine and Advanced Airway Placement After Out-of-Hospital Cardiac Arrest. JAMA Netw Open. 2024. PMID: 38372996. doi:10.1001/jamanetworkopen.2023.56863
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。